Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Conventional dose still better than reduced dose insulin for hyperkalaemia

02 Jun 2020
Reduced dependence on insulin injections may make patients more inclined to comply with treatment and reduce adverse effects of the injections such as local lipomas or scars.

A recent study has shown that conventional dose insulin remains more effective than reduced dose regular insulin at baseline serum potassium levels >6 mmol/L in the treatment of hyperkalaemia.

“Using a reduced dose of 5 units of regular insulin has been proposed as a strategy to mitigate the risk of hypoglycaemia when treating hyperkalaemia,” according to the authors.

This study compared the effectiveness of reduced vs conventional dosed insulin for hyperkalaemia treatment. The authors reviewed electronic medication administration reports of conventional or reduced doses of insulin given to patients from July 2013 to September 2015. Reduction in serum potassium was the primary outcome.

A total of 92 administrations of reduced dose insulin and 309 administrations of conventional dose insulin were included in the review. There was no significant difference in potassium reduction between the two treatment groups (–0.096 mmol/L; p=0.2210).

In posthoc subgroup analysis of patients with serum potassium >6 mmol/L, results showed a lower decrease in potassium in the reduced dose insulin group compared to the conventional dose insulin group (difference, –0.238 mmol/L; p=0.018).

“Frequent monitoring of serum potassium and glucose after administration of insulin is necessary to confirm adequate response and avoidance of hypoglycaemia,” the authors said.

In contrast, a 2017 study reported that 5 units of insulin reduced serum potassium to the same extent as 10 units of insulin in patients with renal insufficiency and hyperkalaemia, but with a lower hypoglycaemia rate. [Pharmacotherapy 2017;37:1516-1522]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.